In this large multisite study, utilizing data from six population-based databases, we found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer with follow-up ranging from 1.8-3.0 years, providing some reassurance to patients and clinicians about the short-term safety of these drugs, concluded the investigators
For cardiovascular risk reduction in non-diabetic patients, semaglutide has stronger published evidence (SELECT trial)
Rybelsus, although made of the same active ingredient, led to 3.7 kg (about 8 lbs) of weight loss over 26 weeks in studies, which is less than the results reported for the injectable forms
Biochemistry 53 , 21852196 (2014)
And moisture
This gradual titration schedule helps minimize gastrointestinal side effects while allowing the body to adapt to the medication's effects